Why did IPCA Laboratories (IPCALAB) stock move recently?

On 8/5/2026, IPCA Laboratories moved +4.1% — No clear company-specific catalyst identified for the 4.15% gain; the stock likely moved with the broader market or pharma sector ahead of the upcoming Q1 results (board meeting scheduled for Aug 13) and dividend ex-date (Aug 7). This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is IPCA Laboratories (IPCALAB) overvalued or fairly valued?

MarketChacha shows IPCA Laboratories's valuation in context — a forward P/E of about 26.6, a price-to-book of about 5.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is IPCA Laboratories's revenue?

IPCA Laboratories reported revenue of ₹7,337 Cr for FY2026, with net profit of ₹1,133 Cr, per official filings.

What is the share price of IPCA Laboratories (IPCALAB)?

IPCA Laboratories last traded at ₹1,748.40 (+3.7% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

IPCA Laboratories

IPCALAB · NSE · Pharma · India

Snapshot

TickerIPCALAB

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees17,210

HeadquartersMumbai, India

Websitewww.ipca.com

Filings tracked1

About IPCA Laboratories

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/protectives, fever, gastroenterology, haematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, regenerative, respiratory, rheumatology, and urology. The company also exports its products to Europe, Africa, the Americas, rest of Asia, the Commonwealth of Independent States, and Australasia. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

Who owns it

Promoters45.1%
Institutions45.2%
Public & other9.8%

78 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend8.7% → 11.8%

Margin has expanded by about 3.1 points — the business is getting more profitable.

Growth qualityrev 13% · PAT 23%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹2,776 Cr

Next fiscal year

Rev ₹12,008 Cr · EPS 65.66

Est. earnings growth +18.9%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Revenue (FY2026)

₹9,646 Cr

Net margin

11.8%

Revenue CAGR (3y)

+18.4%

Profit CAGR (3y)

+31.2%

Net profit (FY2026)

₹1,141 Cr

Ask MarketChacha about IPCALAB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 5, 2026
No clear company-specific catalyst identified for the 4.15% gain; the stock likely moved with the broader market or pharma sector ahead of the upcoming Q1 results (board meeting scheduled for Aug 13) and dividend ex-date (Aug 7).
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹9,646 Cr	₹1,141 Cr	11.8%
FY2025	₹8,940 Cr	₹738 Cr	8.3%
FY2024	₹7,705 Cr	₹547 Cr	7.1%
FY2023	₹5,815 Cr	₹506 Cr	8.7%

Quarterly

Period	Revenue	Net profit	Net margin
Q4 FY26	₹2,388 Cr	₹299 Cr	12.5%
Q3 FY26	₹2,393 Cr	₹326 Cr	13.6%
Q2 FY26	₹2,557 Cr	₹283 Cr	11.1%
Q1 FY26	₹2,309 Cr	₹233 Cr	10.1%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Board Meeting Intimation for Standalone And Consolidated Financial Results For 1St Quarter Ended 30Th June, 2026
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
BSE7/28/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.